ROCHE HOLDING AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 243.4 CHF | +0.06% |
|
-2.60% | -0.37% |
| Jul. 05 | Global markets live: Apple, Samsung, Shell, Tesla, KKR... |  |
| Jul. 05 | Trending : Roche to Halt Lung-Cancer Trials After Treatment Misses Goals | DJ |
| Sales 2024 * | 60.49B 67.55B | Sales 2025 * | 63.93B 71.39B | Capitalization | 197B 220B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.2B 14.73B | Net income 2025 * | 14.63B 16.34B | EV / Sales 2024 * | 3.49 x |
| Net Debt 2024 * | 14.29B 15.96B | Net Debt 2025 * | 9.23B 10.31B | EV / Sales 2025 * | 3.22 x |
| P/E ratio 2024 * |
14.2
x | P/E ratio 2025 * |
12.8
x | Employees | 103,605 |
| Yield 2024 * |
4.02% | Yield 2025 * |
4.13% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More press releases
More news
| 1 day | +0.18% | ||
| 1 week | -2.68% | ||
| Current month | -2.44% | ||
| 1 month | +1.54% | ||
| 3 months | +10.74% | ||
| 6 months | -3.20% | ||
| Current year | -0.45% |
1 week
238.10
249.30
1 month
238.10255.50
Current year
212.90255.90
1 year
212.90277.25
3 years
212.90404.20
5 years
212.90404.20
10 years
206.35404.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 66 | 95-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.03% | 121 M€ | -.--% | - | |
| 8.46% | 21 M€ | +10.60% | - | |
| 4.67% | 2 M€ | -.--% | ||
| 2.85% | 6 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-08 | 243.6 | +0.12% | 97 115 |
| 24-07-05 | 243.3 | -0.04% | 757,877 |
| 24-07-04 | 243.4 | -1.06% | 1,296,765 |
| 24-07-03 | 246 | -1.01% | 929,796 |
| 24-07-02 | 248.5 | -0.64% | 1,032,254 |
Delayed Quote Swiss Exchange, July 08, 2024 at 04:40 am EDT
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
243.3
CHF
Average target price
276.6
CHF
Spread / Average Target
+13.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.45% | 219B | |
| +56.89% | 823B | |
| +40.64% | 627B | |
| -6.55% | 353B | |
| +15.99% | 320B | |
| +7.92% | 295B | |
| +14.11% | 239B | |
| +14.28% | 220B | |
| +7.94% | 167B | |
| -2.57% | 159B |
- Stock Market
- Equities
- ROG Stock
